BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Augustin J, Gabignon C, Scriva A, Menu L, Calmel C, Scatton O, Paye F, Fléjou JF, Praz F, Cervera P, Wendum D. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. Virchows Arch 2020;477:33-45. [PMID: 32447492 DOI: 10.1007/s00428-020-02822-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs 2021;30:389-99. [PMID: 33218269 DOI: 10.1080/13543784.2021.1854724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Salani F, Ugolini C, Catanese S, Cacciato Insilla A, Fornaro L, Campani D, Vasile E, Fontanini G, Masi G, Vivaldi C. In Reply. Oncologist 2021. [PMID: 34176190 DOI: 10.1002/onco.13886] [Reference Citation Analysis]